BACKGROUND: The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-one women with HER2+ MBC were treated with gemcitabine 1000 mg/m(2) intravenously (I.V.) days 1, 8, and 15 and trastuzumab 4-mg/kg I.V. loading dose and then 2 mg/kg weekly. Cycles were repeated every 28 days. Patients were evaluated after 8 weeks of treatment; responders/stable patients continued treatment until progression. RESULTS: Patients received a median of 28 weeks of treatment. Eleven of 37 evaluable patients (30%; 95% CI, 17%-46%) had major responses. The median progression-free survival (PFS) was 4 months (95% CI, 1.9-5.3 months), with a 1-year PFS of 17%. Four of 15 patients (27%) who had previously received trastuzumab for MBC had partial responses. The gemcitabine/trastuzumab combination was well tolerated. CONCLUSION: The combination of gemcitabine and trastuzumab is an active regimen but appears less active than trastuzumab in combination with either taxanes or vinorelbine. The role of gemcitabine/trastuzumab (versus gemcitabine alone) in women who have already received a trastuzumab-containing regimen for HER2+ MBC is not defined by this study.
BACKGROUND: The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the activity and toxicity of the gemcitabine/trastuzumab combination as first- or second-line treatment in women with HER2+ metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-one women with HER2+ MBC were treated with gemcitabine 1000 mg/m(2) intravenously (I.V.) days 1, 8, and 15 and trastuzumab 4-mg/kg I.V. loading dose and then 2 mg/kg weekly. Cycles were repeated every 28 days. Patients were evaluated after 8 weeks of treatment; responders/stable patients continued treatment until progression. RESULTS:Patients received a median of 28 weeks of treatment. Eleven of 37 evaluable patients (30%; 95% CI, 17%-46%) had major responses. The median progression-free survival (PFS) was 4 months (95% CI, 1.9-5.3 months), with a 1-year PFS of 17%. Four of 15 patients (27%) who had previously received trastuzumab for MBC had partial responses. The gemcitabine/trastuzumab combination was well tolerated. CONCLUSION: The combination of gemcitabine and trastuzumab is an active regimen but appears less active than trastuzumab in combination with either taxanes or vinorelbine. The role of gemcitabine/trastuzumab (versus gemcitabine alone) in women who have already received a trastuzumab-containing regimen for HER2+ MBC is not defined by this study.
Authors: Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni Journal: Nat Rev Clin Oncol Date: 2011-11-29 Impact factor: 66.675
Authors: Ines Vaz-Luis; Davinia Seah; Erin M Olson; Nikhil Wagle; Otto Metzger-Filho; Jessica Sohl; Georgia Litsas; Harold J Burstein; Ian E Krop; Eric P Winer; Nancy U Lin Journal: Clin Breast Cancer Date: 2013-08 Impact factor: 3.225
Authors: Alison T Stopeck; Ursa Brown-Glaberman; Hong Yuen Wong; Ben Ho Park; Sara E Barnato; William J Gradishar; Clifford A Hudis; Hope S Rugo Journal: Clin Exp Metastasis Date: 2012-06-13 Impact factor: 5.150
Authors: Sandra M Swain; Sung-Bae Kim; Javier Cortés; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Adam Knott; Emma Clark; Graham Ross; Mark C Benyunes; José Baselga Journal: Lancet Oncol Date: 2013-04-18 Impact factor: 41.316
Authors: Kathy Miller; Javier Cortes; Sara A Hurvitz; Ian E Krop; Debu Tripathy; Sunil Verma; Kaveh Riahi; Joseph G Reynolds; Thomas J Wickham; Istvan Molnar; Denise A Yardley Journal: BMC Cancer Date: 2016-06-03 Impact factor: 4.430